Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-30 1:25 pm Purchase | 2025-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | The Vanguard Group | 2,007,193 6.380% | 2,007,193 (New Position) | Filing History |
| 2026-01-09 4:45 pm Sale | 2026-01-07 | 13D | Cidara Therapeutics, Inc. CDTX | RA Capital Management, L.P. | 0 0.000% | -3,372,923 (Position Closed) | Filing History |
| 2025-11-17 4:39 pm Unchanged | 2025-11-13 | 13D | Cidara Therapeutics, Inc. CDTX | RA Capital Management, L.P. | 3,372,923 10.700% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:39 pm Sale | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | Commodore Capital LP | 585,000 2.000% | -590,000 (-50.21%) | Filing History |
| 2025-11-14 4:34 pm Sale | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | Paradigm BioCapital Advisors LP | 961,164 3.300% | -167,449 (-14.84%) | Filing History |
| 2025-11-14 4:30 pm Purchase | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BCLS Fund III Investments LP | 3,020,990 9.990% | 520,310 (+20.81%) | Filing History |
| 2025-11-14 4:23 pm Sale | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | TCG Crossover GP II, LLC | 0 0.000% | -1,005,901 (Position Closed) | Filing History |
| 2025-11-14 4:12 pm Purchase | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 1,578,069 6.200% | 50,139 (+3.28%) | Filing History |
| 2025-11-10 4:40 pm Purchase | 2025-11-06 | 13D | Cidara Therapeutics, Inc. CDTX | RA Capital Management, L.P. | 3,372,923 10.700% | 7,400 (+0.22%) | Filing History |
| 2025-10-17 6:40 pm Purchase | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BlackRock Inc. BLK | 1,163,607 4.600% | 55,939 (+5.05%) | Filing History |
| 2025-10-17 4:48 pm Sale | 2025-10-15 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 1,189,165 4.400% | -225,000 (-15.91%) | Filing History |
| 2025-10-17 4:45 pm Purchase | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 1,414,165 5.200% | 161,724 (+12.91%) | Filing History |
| 2025-08-14 5:59 pm Sale | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | Venrock Healthcare Capital Partners III, L.P. | 639,088 3.200% | -459,908 (-41.85%) | Filing History |
| 2025-08-14 5:28 pm Purchase | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 1,527,930 7.600% | 528,516 (+52.88%) | Filing History |
| 2025-08-14 4:30 pm Sale | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | Canaan XII L.P. | 0 0.000% | -1,400,000 (Position Closed) | Filing History |
| 2025-08-14 4:00 pm Purchase | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | BCLS Fund III Investments LP | 2,500,680 9.990% | 1,797,600 (+255.68%) | Filing History |
| 2025-08-12 8:50 pm Purchase | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | Vivo Opportunity Fund Holdings, L.P. | 1,175,796 4.600% | 563,520 (+92.04%) | Filing History |
| 2025-08-12 09:02 am Purchase | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | Adage Capital Management, L.P. | 1,100,000 4.970% | 110,000 (+11.11%) | Filing History |
| 2025-08-11 4:43 pm Unchanged | 2025-08-07 | 13D | Cidara Therapeutics, Inc. CDTX | RA Capital Management, L.P. | 3,365,523 13.300% | 0 (Unchanged) | Filing History |
| 2025-07-30 4:14 pm Purchase | 2025-07-23 | 13G | Cidara Therapeutics, Inc. CDTX | Paradigm BioCapital Advisors LP | 1,128,613 5.600% | 1,128,613 (New Position) | Filing History |